The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The current treatment algorithm for follicular lymphoma and how this is evolving
In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, outlines the current treatment algorithm for follicular lymphoma, which is evolving with a shift away from chemotherapy, and highlights the use of CD20-targeting therapies such as rituximab and obinutuzumab in frontline and relapsed settings. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Follicular lymphoma has historically been treated with chemoimmunotherapy in frontline, and that’s still what happens in the majority of community settings. Bendamustine-rituximab is a regimen which is most commonly used based on StiL and BRIGHT studies. Bendamustine-obinutuzumab is also used based on the GALLIUM study. But in academic institutions like ours, often lenalidomide-based therapies are put in the front lines, such as lenalidomide-rituximab or lenalidomide-obinutuzumab...
Follicular lymphoma has historically been treated with chemoimmunotherapy in frontline, and that’s still what happens in the majority of community settings. Bendamustine-rituximab is a regimen which is most commonly used based on StiL and BRIGHT studies. Bendamustine-obinutuzumab is also used based on the GALLIUM study. But in academic institutions like ours, often lenalidomide-based therapies are put in the front lines, such as lenalidomide-rituximab or lenalidomide-obinutuzumab. And the RELEVANCE study has shown that lenalidomide-based therapies are essentially non-inferior to chemoimmunotherapy.
In relapsed follicular lymphoma, there is now exciting development with recent approval of the EPCO-R-squared regimen in the United States based on a randomized study which randomized patients to epcoritamab-R-squared versus R-squared alone. And that study showed improvement in response rate and improvement in progression-free survival in favor of EPCO-R squared without necessarily a significant increase in toxicity. So I believe that has become a new standard of care in second-line follicular lymphoma.
And then in third line, we have bispecific antibody options such as mosunetuzumab, epcoritamab, which have been approved. We also have CD19 targeting CAR T-cells. And we have the ROSEWOOD regimen, which is zanubrutinib-obinutuzumab. So there is an ongoing shift away from chemotherapy in follicular lymphoma that is happening. And I do believe we will soon arrive into a chemotherapy-free future as these regimens such as EPCO-R-squared are now being investigated in frontline.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
